New Oral Weight-Loss Drug Foundayo Offers Convenient Alternative to Mounjaro in Obesity Fight

A new weight-loss medication has captured the attention of health professionals and patients alike, offering hope to those struggling with obesity. Known as Foundayo, this once-daily oral tablet has been informally referred to as the 'Mounjaro pill' due to its similar mechanism of action to the popular injectable drug Mounjaro. The medication works by targeting hormones that regulate appetite, helping users feel fuller for longer and reducing food intake. Unlike traditional injectable treatments, Foundayo is taken orally, making it more convenient for patients and potentially increasing its accessibility if approved for wider use.

Clinical trial participant Maggie Linton, a 77-year-old US-based volunteer in a MedStar Health study, shared her experience with the drug. She reported noticeable changes within weeks of starting the medication, including improvements in weight, cholesterol levels, and overall health. Over the course of two years, she lost approximately 3.6 stone, dropping from 16.7 stone to 13.2 stone. Linton described the side effects as mild, with only brief episodes of constipation at the beginning of treatment. She emphasized that lifestyle changes, such as walking, tai chi, and Pilates, played a crucial role in maintaining her progress alongside the medication.

Experts highlight the potential of oral GLP-1-based treatments like Foundayo, which have already transformed weight-loss care through drugs such as Ozempic and Mounjaro. These medications work by mimicking the hormone GLP-1, which helps regulate appetite and blood sugar levels. The appeal of oral formulations lies in their convenience compared to injectable alternatives, which may encourage more people to seek treatment. However, healthcare professionals caution that such drugs are not a standalone solution. They stress that the most effective outcomes are achieved when these medications are combined with dietary changes and increased physical activity.

Foundayo is being developed by pharmaceutical giant Eli Lilly, which has cleared the drug for use in the United States. The US Food and Drug Administration (FDA) approved the medication following large clinical trials that demonstrated its efficacy. These trials showed that the drug is as effective as injectable versions of similar medications. The approval has generated significant interest globally, as the obesity treatment landscape continues to shift toward easier-to-administer oral options.

The success of oral GLP-1 drugs is not limited to Foundayo. In January, a pill version of Wegovy—a blockbuster slimming drug—was launched in the United States. Wegovy, developed by Danish pharmaceutical company Novo Nordisk, contains 25mg of semaglutide, the same active ingredient used in injectable Wegovy and the diabetes drug Ozempic. While Ozempic is primarily licensed to treat type 2 diabetes, it is often prescribed off-label for weight loss. In contrast, Wegovy was specifically designed and approved for obesity management.

Trials involving over 1,300 participants found that individuals taking the Wegovy pill lost an average of 16.6% of their body weight after just over a year. This outcome has reinforced the potential of oral GLP-1 drugs to deliver significant weight loss results. Novo Nordisk is currently working on bringing the pill version of Wegovy to the UK, with a regulatory submission planned for 2026. A spokesperson for Novo Nordisk UK confirmed this timeline but noted that further details on the submission process are not yet available.

Despite the promising results, healthcare experts continue to emphasize the importance of caution when using these medications. While they can be highly effective, they are not without risks. Common side effects include nausea, digestive issues, and in rare cases, more serious complications. Patients are advised to consult with their healthcare providers to determine if these medications are appropriate for their individual needs and to ensure they are used in conjunction with healthy lifestyle choices.

As the development and approval of oral GLP-1 drugs continue to advance, they represent a significant step forward in the treatment of obesity. These medications offer a more convenient alternative to injectable treatments while maintaining the same level of efficacy. However, their success depends on a holistic approach that includes proper nutrition, regular physical activity, and ongoing medical supervision. With continued research and regulatory approvals, oral GLP-1 drugs may become a cornerstone of obesity management in the years to come.